Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity
Objective: To describe baseline characteristics and treatment patterns in patients with chorea associated with Huntington disease (HD) by severity of chorea. Background: Though multiple treatment…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex
Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS
Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…VMAT2 availability in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder
Objective: To use [11C]DTBZ PET imaging to explore vesicular monoamine transporter 2 (VMAT2) availability in Parkinson’s disease (PD) with and without rapid eye movement sleep…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US
Objective: To summarize clinical experience and outcomes with deutetrabenazine (DTBZ) as a treatment for Huntington’s disease (HD) chorea from the Huntington’s Disease Society of America…Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.